Application of a compound in the preparation of drugs for the treatment of viral pneumonia

A technology for viral pneumonia and compounds, applied in the field of medicine, can solve the problems of lack of new antiviral drugs, etc., and achieve superior antiviral pneumonia effect, raw material economy, and strong antiviral effect.

Active Publication Date: 2021-05-07
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] One of the purposes of the present invention is to propose the application of a compound in the preparation of drugs for the treatment of viral pneumonia, which solves the technical problem of lack of new antiviral drugs in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a compound in the preparation of drugs for the treatment of viral pneumonia
  • Application of a compound in the preparation of drugs for the treatment of viral pneumonia
  • Application of a compound in the preparation of drugs for the treatment of viral pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] This example provides the effect of combined drugs on coronavirus pneumonia.

[0025] Experimental method: C57BL / 6 mice (20-25g) were randomly divided into 5 groups according to different body weights, namely: group A, blank control group; group B, HcoV-OC43 virus model group; group C, HcoV-OC43 virus model group Compound 1 group; D group, HcoV-OC43 virus compound 2 group; E group, HcoV-OC43 virus compound 1 and 2 combination group (low dose); F group, HcoV-OC43 virus compound 1 and 2 combination group (high dose) ; Group G, positive drug ribavirin group; H group, positive drug oseltamivir group. Animals in all groups were anesthetized with propofol tail vein, except for the blank control group, they were all infected with HcoV-OC43 virus solution (30 μL) by intranasal drip. Subsequent processing is as follows:

[0026] Group A mice: intragastric administration of the same dose of normal saline in the drug intervention group;

[0027] Group B mice: intragastric admin...

Embodiment 2

[0041] This example provides the effect of combined drugs on influenza A virus pneumonia.

[0042] Experimental method: C57BL / 6 mice (20-25g) were randomly divided into 5 groups according to body weight: Group A, blank control group, group B, H1N1 virus model group, group C, H1N1 virus compound 1 group, D Group, H1N1 virus compound 2 group, E group, H1N1 virus compound 1 and 2 combination group (low dose), F group, H1N1 virus compound 1 and 2 combination group (high dose), G group, positive drug ribavirin group , group H, positive drug oseltamivir group. Animals were anesthetized with propofol through the tail vein, and were infected with H1N1 virus solution (30 μL) by intranasal drip except for the blank control group. Subsequent operations:

[0043] Group A mice: The intervention group was given the same dose of normal saline by intragastric administration of drugs;

[0044] Group B mice: intragastric administration of drugs to give the intervention group the same dose of...

Embodiment 3

[0058] This example provides a synthesis method of the purine compound (1-ethyl-3-7-dimethylxanthine) with the structure of formula 1.

[0059] Take 540mg (3mmoL) of theobromine and 720mg (30mmol) of NaH dissolved in 80mL of DMF, and add 2mL of iodoethane (24.7mmol) dropwise under stirring. After reacting for 4 hours, add water to quench the reaction, spin dry under reduced pressure, and separate on a silica gel column (mobile phase; petroleum ether: CH 3 CH 2 OCOCH 3 =3:1) The product compound 1-ethyl-3-7-dimethylxanthine (495mg, 2.5mmol, 85%) was obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of a compound in the preparation of drugs for treating viral pneumonia, relates to the field of medical technology, and solves the technical problem of lack of new antiviral drugs in the prior art. The compounds of the present invention include purine compounds with the structure of formula 1 and / or anthraquinone derivatives with the structure of formula 2. The purine compound with the structure of formula 1 of the present invention and the anthraquinone derivative with the structure of formula 2 exhibit superior antiviral pneumonia effects whether used alone or in combination; the medicine for treating viral pneumonia prepared by using the compound provided by the present invention, Compared with clinical first-line drugs, the activity is more significant, and it is better than drugs such as ribavirin and oseltamivir.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a compound in the preparation of a drug for treating viral pneumonia. Background technique [0002] Viral pneumonia is an inflammation of the lungs caused by the downward spread of a virus infected by the upper respiratory tract. Viral pneumonia can occur at any time of the year, but it breaks out and becomes popular in winter and spring. The main clinical manifestations are fever, headache, body aches, dry cough, and lung infiltration. The incidence of viral pneumonia is often related to the virulence of the virus, the route of infection, the age of the host, and the immune status. The disease occurs more frequently in the elderly and children. In the case of acute respiratory infection, the virus infection rate can be as high as 90%, and the upper respiratory tract infection is the main route, which is divided into diseases such as common cold, pharyngitis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/522A61K31/122A61P31/16A61P31/14A61P11/00
CPCA61K31/122A61K31/522A61P11/00A61P31/14A61P31/16A61K2300/00
Inventor 黄文张伯礼李幼平张俊华钮海辛光
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap